|
Samuel P. Wertheimer, Ph.D., Dr. Wertheimer joined OrbiMed in 2000 and is a Principal in the private equity funds management group. Dr. Wertheimer�s prior experience includes work in biotechnology finance, technology transfer, intellectual property and research in immunology and molecular biology. Dr. Wertheimer was a Fellow at the Memorial Sloan-Kettering Cancer Center. Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. He has served as a Director of Salmedix and Corus Pharma and currently serves on the boards of several private biotechnology companies including Biodel and ChemoCentryx. | 